June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Prevalence of Preexisting Conditions in Thyroid Eye Disease Patients Who are Candidates for Teprotumumab Therapy from a Single Center in the United States
Author Affiliations & Notes
  • Jason Lin Chien
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Gary J Lelli
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Footnotes
    Commercial Relationships   Jason Chien, None; Gary Lelli, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2937. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jason Lin Chien, Gary J Lelli; Prevalence of Preexisting Conditions in Thyroid Eye Disease Patients Who are Candidates for Teprotumumab Therapy from a Single Center in the United States. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2937.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Teprotumumab (Tpmb), a human monoclonal antibody that inhibits insulin-like growth factor I receptor, is a new drug recently approved by the Food and Drug Administration to treat thyroid eye disease (TED). Mild or moderate adverse events (Table 1) have been associated with patients treated with Tpmb.There is limited information regarding the prevalence of preexisting conditions that may potentially be exacerbated by Tpmb therapy in TED patients. To investigate the prevalence of preexisting conditions in TED patients who are candidates for Tpmb therapy in the United States.

Methods : Tpmb related adverse events from previously published report were identified (Table 1). A retrospective chart review for all patients who were evaluated for TED by a single oculoplastic surgeon at the Department of Ophthalmology of Weill Cornell Medical College were screened for preexisting conditions that may potentially be exacerbated by Tpmb therapy (Table 1).

Results : One hundred fifty-three patients were screened (121 female, 32 male). Mean age was 50.8 years old (range 25 to 84 years old). The prevalence of celiac disease (2.0%), IBD (1.3%), chronic diarrhea (0.7%), diabetes mellitus (11.8%), alopecia areata (0.7%), chronic headaches (migraines, tension, and/or clustered)(7.8%), peripheral neuropathy and/or paresthesia (2.0%), hearing impairment (0.7%), and low body weight (0.0%) were recorded (Table 2).

Conclusions : Previously, a study from Germany reported the prevalence of celiac disease, type 1 diabetes mellites, and alopecia areata in Graves’ disease patients (Table 2).Another report showed a decrease in hearing ability in Graves’ disease patients, particularly at high frequencies. No report to date have investigated the prevalence of these conditions specifically in TED patients who are candidates for Tpmb therapy in the United States. In January 2020, the TED Center at Weill Cornell Medical College/New York Presbyterian Hospital will be the first and largest center in New York City to implement Tpmb therapy for TED. Understanding the prevalence of preexisting conditions in TED patients who are candidates for Tpmb therapy allows clinicians to better anticipate for exacerbation of these preexisting conditions with Tpmb therapy.

This is a 2020 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×